期刊
JOURNAL OF INFECTIOUS DISEASES
卷 224, 期 10, 页码 1712-1719出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiab206
关键词
topical; adjuvant; influenza; vaccine
资金
- National Institutes of Health [HHSN272201300015I, HHSN272201500002C]
The study concluded that the combination of topical imiquimod with ID MIV A/H5N1 was safe but did not result in improved serologic responses to the vaccine.
Background. Safe, effective, and easy to deploy adjuvants are needed for influenza prepandemic preparedness. Based on recent reports, we hypothesized that preapplication of topical imiquimod followed by intradermal (ID) vaccination with monovalent inactivated influenza A/H5N1 vaccine (MIV A/H5N1) results in improved serologic responses. Methods. We randomized 50 healthy adults in a 1:1 ratio to receive topical imiquimod (group 1) or control cream (group 2) followed by ID injection of 9 mu g of the hemagglutinin MIV A/H5N1 in 2 doses, 21 days apart. Subjects were followed for safety and serologic responses as measured by the hemagglutination inhibition (I IAI) and microneutralization (MN) assays. Results. Solicited and unsolicited adverse events were comparable between groups 1 and 2, and were mostly mild to moderate in severity. At 21 days after dose 2, the geometric mean titers (GMTs) of HAI antibodies against the vaccine strain were 16.2 and 24.3 in groups 1 and 2, respectively. The MN antibody GMTs were 9.3 and 10.7 in groups 1 and 2, respectively. There were no significant differences in antibody levels between groups at study time points. Conclusions. Topical imiquimod administration combined with ID MIV A/H5N1 was safe but did not result in improved serologic responses to the vaccine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据